Silexion Therapeutics Corp. announced new preclinical data showing successful distribution of SIL204 to liver, peritoneum, and lung with measurable reductions in tumor burden in pancreatic cancer metastasis. This validates the systemic component of their dual-route administration strategy and supports potential targeting of primary tumors and metastatic disease. Phase 2/3 trial initiation is on track for H1 2026 after planned regulatory submissions in Q4 2025 and Q1 2026. The ability of SIL204 to reach metastatic sites is crucial, as over 80% of pancreatic cancer mortality is due to metastatic disease. The study used human equivalent doses to achieve relevant results for planned clinical use.

Read more at GlobeNewswire: Silexion Therapeutics Reports Positive Preclinical Data